Core Insights - Several biotech and healthcare stocks experienced significant after-hours trading gains due to clinical updates, strategic deals, and regulatory milestones [1] Company Summaries - **Genenta Science S.p.A. (GNTA)**: Shares closed at $2.40, down 27.71% during regular trading, but rebounded to $2.45, up 2.08% in after-hours. The volatility was driven by a $15 million registered direct offering and a strategic collaboration announcement [2] - **EDAP TMS S.A. (EDAP)**: Closed at $1.81, down 22.58%, but rose 8.29% to $1.96 in after-hours trading. The recovery appears technical, with no new news, and is supported by upcoming investor meetings at the UBS Global Healthcare Conference [3] - **BridgeBio Pharma Inc. (BBIO)**: Ended regular trading at $64.50, up 1.48%, and climbed 6.71% to $68.83 after hours. The increase reflects anticipation for Phase 3 CALIBRATE trial results for ADH1, with topline data expected on October 29 [4] - **OrthoPediatrics Corp. (KIDS)**: Closed at $16.91, down 0.29%, but surged 6.45% to $18.00 after releasing Q3 financial results, reporting a GAAP loss per share of $(0.50) despite 12% revenue growth [5][6] - The company raised its full-year 2025 revenue guidance to $233.5 million to $234.5 million, indicating projected growth of 14% to 15% compared to the prior year [7] - **Modular Medical Inc. (MODD)**: Dipped 1.30% to $0.5392 but rallied 5.38% to $0.5682 after hours following the successful completion of its Stage 1 ISO 13485:2016 audit, a key step toward CE Mark certification [8] - **Vivani Medical Inc. (VANI)**: Rose 3.09% to $1.67 and added 3.65% to $1.7310 after closing a $15.7 million capital raise, which included a registered direct offering and private placement, indicating insider confidence [9] - **Amarin Corp. plc (AMRN)**: Slipped 1.56% to $18.94 but rebounded 5.07% to $19.90 after the FDA revised fenofibrate drug labeling, which may favor Amarin's Vascepa in the lipid management space [10]

Core Insights - OrthoPediatrics Corp. has successfully completed the first U.S. surgical procedures using the VerteGlide Spinal Growth Guidance System to treat Early Onset Scoliosis (EOS) [1][2] Company Overview - OrthoPediatrics, founded in 2006, focuses exclusively on pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions [5] - The company markets over 80 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [5] - OrthoPediatrics distributes its products in the United States and over 70 countries globally [5] Product Details - The VerteGlide system is part of OrthoPediatrics' Scoliosis suite and provides a unique alternative for treating scoliosis, leveraging advanced implant and instrument technology [3] - This system addresses complex spinal pathologies in early onset scoliosis patients and is designed with input from a team of expert surgeons [4] - The technology behind VerteGlide is based on Shilla™ technology licensed from Medtronic [4] Clinical Impact - The initial procedures using VerteGlide have been reported as a great success, addressing a significant unmet clinical need for EOS patients [2] - The system is expected to greatly benefit current and future patients, providing a cutting-edge solution for complex spinal conditions [2][4] Upcoming Events - VerteGlide will be featured at the 60th Annual Meeting of the Scoliosis Research Society in September and the 19th International Congress on Early Onset Scoliosis in November [3]